<DOC>
	<DOCNO>NCT02096458</DOCNO>
	<brief_summary>The purpose study measure in-vivo disintegration time single dexlansoprazole delayed-release orally disintegrate ( OD ) tablet .</brief_summary>
	<brief_title>Sensory Evaluation Dexlansoprazole Delayed-Release Orally Disintegrating Tablets</brief_title>
	<detailed_description>The drug test study call dexlansoprazole . An orally disintegrating ( OD ) form dexlansoprazole test look average time take one tablet disintegrate mouth healthy volunteer . At point panelist would normally swallow granule , record time expectorate disintegrate tablet mass actually swallow tablet granule . The study enroll approximately 8 healthy volunteer . All participant take one dexlansoprazole 30 mg OD tablet three separate study day . No 60 mg dexlansoprazole test one day . This single-centre trial conduct United States . The overall time participate study approximately 2 week . Participants make 4 visit clinic , contact telephone approximately 1 week last dose study drug follow-up assessment .</detailed_description>
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<mesh_term>Esophagitis</mesh_term>
	<mesh_term>Heartburn</mesh_term>
	<mesh_term>Dexlansoprazole</mesh_term>
	<mesh_term>Lansoprazole</mesh_term>
	<criteria>1 . The male female sensory panelist 25 80 year age ( inclusive ) , healthy volunteer study participation , able read , understand , sign date write informed consent form ( ICF ) require privacy authorization study participation . 2 . In opinion investigator , participant capable understand comply protocol requirement . 3 . The sensory panelist qualify base documented training experience : All panelist provide Senopsys , LLC : Panelists train detect , identify , recognize , accurately describe different taste element flavor combination measure oral disintegration time . Training initially accomplish taste model compound learn recognize describe accurately . These ability hone refined additional experience perform product testing . 1 . Has history illness , opinion investigator sensory panelist 's general practitioner , might confound result study pose additional risk administer study drug ( ) sensory panelist . This may include limited : history relevant drug food allergy ; history cardiovascular central nervous system disease ; history presence clinically significant pathology ; recent history disease involve head , neck , esophagus ( especially malignancy , radiation therapy , fungal infection taste perception alter ) history mental disease . 2 . If female , sensory panelist pregnant , nursing , plan become pregnant study . 3 . Has know hypersensitivity dexlansoprazole component dexlansoprazole delayedrelease orally disintegrate ( OD ) tablet proton pump inhibitor ( PPI ) ( include lansoprazole , omeprazole , rabeprazole , pantoprazole , esomeprazole ) . 4 . Is currently take contraindicate medication .</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Drug therapy</keyword>
</DOC>